Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L29 pseudogene 11 (RPL29P11) is a processed pseudogene in the human genome. Pseudogenes are segments of DNA that arise from functional genes but have lost their ability to produce functional proteins, typically due to mutations or loss of regulatory elements. RPL29P11 is one of several pseudogenes related to the ribosomal protein L29 gene (RPL29), which encodes a structural protein of the large 60S ribosomal subunit. Like most ribosomal protein pseudogenes, RPL29P11 does not have any known functional role, biological activity, or direct involvement in disease. It is not a drug target, nor is it considered a biomarker for disease monitoring or therapeutic response. Its primary relevance is genomic annotation rather than medical or functional significance[7][1][3]. The true ribosomal protein L29 is a structural component of the ribosome, but RPL29P11 is a non-coding pseudogene and does not encode this protein[5][3]. It is cataloged in gene databases and may be referenced in studies of genomic structure or pseudogene biology, but not as a receptor, enzyme, transporter, or other classical drug target[7][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 11 (RPL29P11).